



YORK AGAINST CANCER

**A company limited by guarantee
and
A registered charity number 1130835**

REPORT AND ACCOUNTS

For the year ended

31 December 2022

**HPH
Chartered Accountants
54 Bootham
York
YO30 7XZ**

YORK AGAINST CANCER

CONTENTS

	Page
Chairman's Report	1
Trustees' Report	2 - 16
Auditor's Report	17 – 20
Statement of Financial Activities	21
Balance Sheet	22
Cash Flow Statement	23
Notes to the Financial Statements	24 - 34

YORK AGAINST CANCER

CHAIRMAN'S REPORT 2022

We at last started to see the end of restrictions that had severely hampered the valuable work that the Charity undertakes and getting back to being as normal as possible was a great tonic, with the opportunity to once again meet together at various functions and events being a very positive step.

Once again, we sadly lost a number of our volunteers and supporters throughout the year, and our thoughts go out to their families and friends. Each one of them supported the work of the Charity, and helped it continue to provide the important services and funding for research that we are recognised for.

A number of projects that were under evaluation last year have progressed. These include a £680,000 donation to the York and Scarborough Hospitals NHS Foundation Trust to enable it to acquire a new robotic surgical system, and the start of work on the Leveson Centre, a new cancer support centre located close to our main office at the Community Stadium. We also, at last, managed to source a replacement for the minibus.

Our small office team and mini-bus drivers continued to work hard throughout the year, and to them, our volunteers, and Board colleagues I would like to pass on my grateful thanks for continuing to support and promote the Charity.

Work of course continues, and the need to look forward and plan for our future funding requirements goes on to ensure we remain focused, and in a position to provide the important services for people touched by cancer – services that remain important as we expand on the outstanding work undertaken in the many areas that the Charity is involved in.

It is 35 years since the Charity was created by Professor Steve Leveson, then a consultant surgeon at St James' Hospital in Leeds, and fellow surgeon John Craven and University Researcher Dr. Colin Garner. Its longevity is not only down to their vision but is also a testament to the work undertaken by everybody who is or has been involved with the Charity.

Steve Leveson and his Wife Pat remain an integral part of the Charity, and with our committed army of volunteers, our small band of dedicated staff, and our many supporters the Charity remains in good hands.

Ian Yeowart
Chair York Against Cancer

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2022.

Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding and the provision of services and resources for patients and their families
- funding of research programmes
- funding of education initiatives

Achievements and performance

SUPPORT ACTIVITIES

The Office Team

The office team have settled into their new working environment within York Stadium and are building business relationships with other key stakeholders. They continue to deal with the complex operational challenges that arise, and they do this with great resolve and in a positive manner. Each member of the team has their own responsibilities; however, they support each other with day-to-day tasks, ensuring the smooth operation of the charity and everyone receives the support they need. They respond quickly to any requests and challenges they are faced with, and this is recognised as a key strength of the team.

Services and posts supported by York Against Cancer

- **Health Welfare Advisor - Scarborough**

The charity continues to support the Citizens Advice North Yorkshire (CANY) in their work with cancer patients in the Scarborough area: ensuring that they receive the help to which they are entitled. The area of specialist help includes the following areas.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

ISSUE	Patients concerns
· Benefits	97%
· Charitable applications	15%
· Health & Community Care	5%
· Debt	2%
· Financial services	4%
· Employment	2%
· Housing	5%
· Travel & Transport	6%

It is hoped we will be able to replicate the above post to be based in York and to operate out of the Leveson Centre.

Supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

- **Teenage Psychology Support**

YAC funds a psychologist who specialises in supporting young people when they or their family is affected by cancer. This service is funded on a need basis, during 2022 the charity spent £11k on this service. The psychologist receives her referrals from Clinical Nurse Specialists, Oncologists and G. P's.

- **Mobile Chemotherapy Unit**



The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients the time-consuming and tiring journeys to the hospital in York. During 2022 we continued to fund the cost of servicing and repairs to keep the MCU on the road.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

- **Minibus**

Our minibus service continues to be popular; we provide free transport for patients going to St James hospital in Leeds for radiotherapy treatments. During 2022 we provided 867 single trips to Leeds – radiotherapy is given daily (Mon-Fri) and length of treatments can range from 3 to 7 weeks. If the demand is low, we use the YAC car, making the service more efficient and if we need to we use volunteer drivers.

In 2022 we purchased a new Minibus as pictured.



The following are a few comments received from users of the minibus service.

'Thank you for what you do – your minibus service is amazing and appreciated.'

'Just to say thank you. The bus to Leeds was a God send. It was good fun with the people on the bus.'

'Thank you for your kindness and help getting to St James hospital.'

- **The provision of patient transport to Rapid Diagnostic appointments.**

Patients needing to access diagnosis appointments quickly are offered a rapid diagnostic appointment, this may not be at their nearest hospital which can create problems with attendance. YAC was approached at the end of 2021 asking if we could help with transport. A proposal was put to the YAC board and during 2022 we provided transport to 36 patients at an approximate cost of £2k.


DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES


- **Respite Properties**

The Respite house in Filey continues to provide a welcome break for cancer patients, during 2022 90 patients, their family and friends enjoyed a stay. Many families donate their deposit as way of a thank you and we encourage them to give us feedback, this ensures we hear about their stay and of course so we can act on any improvements needed.


The following are a few comments we have received.




'Thank you for all you do for cancer patients. We had an amazing break and will treasure all the memories.'



'We just wanted to say a huge thank you, for making it possible for us all to have a lovely few days together, stress free.'



'I cannot thank you enough. My holiday in the Filey house was just what I needed. It has done me the world of good after home alone, lockdown and cancer treatment. My friends and I enjoyed a walk by the sea, strolling around Filey and coming back to a cosy house with a beautiful comforting log fire.'



'Thank you so much, our stay in Filey was wonderful and beyond our expectations.'

- **Da Vinci surgical robot.**

In 2022 the YAC board were approached by the York and Scarborough Hospitals NHS Foundation Trust with a proposal to part fund a Da Vinci surgical robot. After the YAC board being shown a presentation which demonstrated this innovative technology they agreed to fund. Surgery performed via the surgical robot is less invasive than open surgery, allowing better precision in difficult to access areas than traditional key-hole surgery, leading to fewer complications, shorter recovery times and overall better outcomes. The board agreed to contribute £680k towards the instruments, training and running costs covering the period 2022-23 to 2024-25; not only does this provide the Trust with a brilliant surgical instrument but it is an investment in advanced technology. By June the robot was fully operational, and it was reported that its value was already being seen.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

- **The Cancer Support Centre – later named The Leveson Centre**

The board of Trustees decided that providing support to local cancer patients via a cancer support Centre was much needed and to create such a facility away from the hospital setting would be a great asset for anyone affected by cancer.

The board agreed to a 10-year lease and set a budget for the fit-out and adaptation of the space.



The whole process was supported by a project team including designers, project management team, builders and including a YAC project team who met fortnightly to make decisions and deal with any issues or concerns as they arose. The project took most of 2022 and with a completion date within the first quarter of 2023.

What your donations do...

Your donations are invaluable to keeping us going and doing all we can to support people affected by cancer.

- £10 → Chat with a cancer support specialist
- £20 → Single minibus trip for 1 patient
- £25 → Complementary therapy treatment
- £50 → 1 night away in our respite home for a family



DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

RESEARCH ACTIVITIES

Clinical Research Nurse and Assistant posts at York Hospital

During 2022 this funding enabled 6 new studies to commence, they were looking at a variety of cancers, cancer genetics and early cancer detection. There are also an additional 13 cancer studies open, 12 of these quickly hit the target number of recruits which would not have been achieved without the YAC funded personnel. The YAC posts also help support some of our long-standing studies, at present there are 25 studies in follow up, many of these studies have 10+ year follow ups.

Excitingly, there are another 14 studies about to be set up in the coming months, and these are in the areas of Haematology, Bowel, Breast, and Head and Neck cancer.

Jack Birch Unit (University of York)

The Charity is committed to another 1 year and 9 months supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

Jack Birch Unit of Molecular Carcinogenesis – Annual Report 2022

The Jack Birch Unit published five research papers in scientific journals this year, covering various aspects of our research. This included a paper presenting evidence supporting Dr Simon Baker's theory that bladder cancer may be caused by a virus. The importance of this work resulted in Simon then being invited to speak at conferences in Palm Springs, Edinburgh and Cambridge!

In March, several of us took part in the 4th Bladder Cancer Translational Research Meeting in London. Then, in October, several members of the team journeyed to Barcelona to the International Bladder Cancer Network conference. Andrew Mason gave a well-received talk, whilst PhD students Ryan Elliott and Vlad Ungureanu presented posters about their research. Andrew and Vlad also presented to the Northern Bioinformatics User Group (NorthernBUG) in Bradford, where Andrew discussed how data from bladder cancer samples can be used to inform patient treatment. Andrew has now finished his YAC-sponsored independent fellowship and moved into the University lectureship position agreed at the time of his appointment. As a result, "cancer informatics" (including large data handling and analysis) is being embedded in biomedical teaching and research at the University and I would like to highlight the critical role that YAC has played in this transformation. Andrew will continue as a key member of the JBU team for his future research.



Dr Simon Baker with the rest of the JBU team in 2022

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

RESEARCH ACTIVITIES

In October, Rachael Moore joined us as a PhD student funded by the Medical Research Council. She is investigating Natural Killer cells and their role in eliminating cancerous cells from normal tissues. During the year we had several undergraduate and masters students working with us, including Lexy (Denise) Barraza, originally from Mexico, who stayed on as a research assistant after the completion of her Master's course. We said farewell to two longstanding members of staff: Dr Jenny Hinley took up training to be a midwife and Dr Jo Pearson took a break and has since returned to work with another cancer group. To fill the vacancy left, we promoted Raphael Slip as our new Technical Team Manager for the JBU. Amongst other activities, several JBU staff took part in the YAC awareness days held in May and October and several female members took part in March in the International Day of Women and Girls in Science.

One of the highlights this year was the conferring of an honorary degree by the University of York to Professor Steve Leveson in recognition of his career in surgery, his role as a cofounder of York Against Cancer and his contribution to the research of the Jack Birch Unit. The University is organising an event for all fundraisers in 2023.

Last, but not least, I would like to thank York Against Cancer Board, fundraisers and supporters for the research support we receive. I also gratefully acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.



**Professor Jenny Southgate, Director,
Jack Birch Unit of Molecular Carcinogenesis, University of York**

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Awareness and Education Committee Report 2022

I would like to thank my fellow members of the group who have continued to work hard during 2022. Our small but committed team has continued to hold hybrid meetings, face to face and zoom.

The Enthuse partnership restarted in May after being stalled due to Covid. Simon Baker has worked closely with the STEM team and with the teachers from participating schools. The focus was to gather data from the schools and to produce relevant lesson plans and to arrange teacher visits the JBU labs and the YAC offices to enable them to find out more about both organisations.

We distributed 911 sun hats to 24 primary schools in the York and surrounding area. Our committed volunteers assisted with the delivery to the participating schools.

We held two awareness days during 2022, in May at the community stadium and in October in the City Centre, both were successful.

As always, the priority of the group is to ensure making the biggest difference with our limited resource. Our recent focus has been to look at local cancer screening uptakes and to compare with the national statistics. This year we looked specifically at bowel cancer screening as it was deemed this screening could be improved upon in Yorkshire. A drinks mat was designed and handed out at events which included both awareness days.

The group is also looking at the local geography and underrepresented groups comparing cancer statistics looking for areas which need our focus. We have contacts within the clinical commissioning group from whom we can get the detailed data on which we can act on in the future.

We are looking at widening our reach across the whole of York and North and East of Yorkshire in collaboration with the communications committee.

As the focus of the group is awareness it was decided the group should be renamed Awareness and Education.

Thank you to the YAC team and the Awareness and Education group members.

Lynn Bartram

Chair, Education and Awareness group

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

FUNDRAISING

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful 'shop front' for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2022 in relation to its fundraising activities.

Fundraising report 2022

This year we have been able to continue rebuilding our fundraising activities which has been a very exciting time for York Against Cancer. We have been able to have more of our regular events again including our awareness days, the golf day and York Rocks Against Cancer. We were so pleased to be able to hold the York Against Cancer Christmas Lunch again this year and also have our in-town Awareness Day – it has been fantastic to see everyone again at all of our events over the course of the year.

As well as holding our own events we have been supported brilliantly by our volunteers, the general public and local businesses who have fundraised for us in various ways including, sponsored walks, head shaves, pantomimes and The Press Cash for Charity initiative. We are also always incredibly grateful to be supported by our volunteers who have helped us this year by attending events, participating in can collections, holding stalls, working in our shops, baking and donating goods for us to sell.

Overall, we have been able to get a lot of our events back in the diary and resume a sense of normality. We are very much looking forward to the next year, fundraising at our established events as well as new opportunities including The Yorkshire 10 Mile and The Total Warrior.

I'd like to take the opportunity to say a big thank you to all of our amazing supporters, with their hard work and efforts York Against Cancer is able to continue what it set out to do – care for, support and educate the people of York and the surrounding areas and also fund ground-breaking research in The Jack Birch Unit at The University of York.

Lauren Hudson

Head of Fundraising and Executive Assistant

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

Future projects to operate out of the Leveson Centre include: -

- Provision of holistic financial and benefits advice / support – via the Citizen Advice York (CAY)
- Complementary Therapy
- Group sessions (including Pre-habilitation)
- Psycho-Oncology support

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to one Board member, Tarnia Hudson, who serves as the Honorary Administrator.

The members of staff employed by the Charity during the year were:

Julie Russell	General Manager, from 4 April CEO
Heather Atkinson	Office & Accounts Manager, from 4 April Deputy CEO and Head of Finance
Lauren Hudson	Personal Assistant to General Manager, from 4 April Head of Fundraising
Nicola Doherty	Office & Volunteer coordinator, from 4 April Head of Administration and Volunteer coordinator
Jill Hutchinson	Head of Retail from 7 March
Jenna Hunton	Retail Assistant from 11 May
Hayley Johnson	Head of Engagement P/T until 17 November
Neil Johnson	Minibus Driver P/T
Garry Stanton	Minibus Driver P/T

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects.

The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Financial review and policies

The Charity's funds in 2022 decreased by £380,991 (2021 - increased by £495,416). Prior to any adjustment for investments, the Charity made a deficit of £351,405 (2021 - surplus of £109,854). The largest commitments in the year were: -

- £680,000 – Funding for Da Vinci surgical robot spread over 3 years.
- £363,262 – Support for the Jack Birch Units research
- £152,221 – Support for another 2 years for the clinical trial nurses
- £432,228 – Investment in the Leveson Centre fitout

The detail of funding of projects can be found in note 6.

The principal funding sources are fund-raising, the trading shops, donations, and legacies. Gross income in 2022 amounted to £1,468,175 (2021 £647,704). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2022. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2022, before fees, was -7.53% (2021 10.99%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2022, before fees, was 7.4% (2021 11.80%).

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reserves Policy

The reserves policy is to ensure the charity holds sufficient funds for the continuation of our support services, whilst maintaining the ability to commitment to future projects. When the Leveson Centre was being planned the trustees understood that this would change the funding model needed for the Charity. The Leveson Centre will increase the operating costs of the charity as we bare all the costs for running the centre.

Cash reserves are accumulated before making a binding commitment to fund set term projects. The total funds held as at 31 December 2022 are £4,397,069 (2021 £4,778,060).

The Board is very mindful that the charity is wholly reliant on donated income and therefore has designated funds for future projects which are under consideration. This ensures its undesignated funds reflect the true level of reserves we hold for future operating commitments.

Undesignated Fund

These are reserves retained to provide working capital and funds for future projects. At the end of the financial year, the unrestricted undesignated reserves were £1,151,686 (2021 £3,041,746). These have decreased as the trustees have designated significant funds to the Leveson Centre, Jack Birch Unit and Health Welfare. The level of free reserves is £725,888 (after excluding lease commitments which we expect to be covered from future annual income). This is the equivalent of 14 months of our budgeted undesignated operating costs. It is the charity's policy to hold 12 months of our operating costs as the charity is largely reliant on donated and legacy income.

Excess reserves will be available for additional fixed term projects or grants not already under consideration.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £3,109,980 (2021 £1,597,671) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £135,403 (2021 £138,643) details of which are given in Note 17 to the financial statements.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

Approved by the Board on 6 June 2023 and signed on its behalf by:

Ian Yeowart
Director and Trustee

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reference and administrative details

Registered Charity	number 1130835	Company Limited by Guarantee	number 06884476
Principal Office and Trading Address	East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF		
Company Secretary	Julie Pamela Russell		
Directors and Trustees	Andrew Proctor Angela Darby Rachel Goddard Michael John Stower William Mark Sessions Ian Yeowart Sarah Wearing	Dr Lynn Bartram Michael Sweet Robert Onyett Tarnia Hudson Prof Stephen Leveson Michael Patrick Shepherd	
	Trustee's protocol available on request		
Accountants	HPH Chartered Accountants 54 Bootham York YO30 7XZ	Auditors	Hentons & Co LLP Chartered Accountants 124 Acomb Road Holgate York YO24 4EY
Bankers	National Westminster Bank 1 Market Street York YO1 8SR	Solicitors	Harrowells Moorgate House Clifton Moorgate York YO30 4WY
Investment Advisors	HSBC Global Asset Management 78 St James's Street London SW1A 1EJ		Ruffer LLP 80 Victoria Street London SW1E 5JL

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2022

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2022 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2022 and of the groups incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2022

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report have been prepared in accordance with applicable legal requirements.

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2022**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

- We have obtained an understanding of the legal and regulatory framework applicable to the group and parent charitable company through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the charitable company is a part of. The charitable company uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the company remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the group and charitable company; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the group's and charitable company's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2022.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the group's and charitable company's controls, and the nature, timing and extend of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2022

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's and charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....
Brett Davis (Senior Statutory Auditor)

For and on behalf of Hentons & Co LLP

Chartered Accountants

Statutory Auditor

124 Acomb Road

York

YO24 4EY

Date: 6 June 2023

YORK AGAINST CANCER
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
AND INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2022 £	Year ended 31 Dec 2021 £
Income and endowments from:						
Donations and legacies	2	1,154,842	-	15,000	1,169,842	403,515
Other trading activities	3	261,895	-	-	261,895	199,087
Investments	4	36,438	-	-	36,438	45,102
Total		1,453,175	-	15,000	1,468,175	647,704
Expenditure on:						
Raising funds	5	259,611	-	-	259,611	199,970
Charitable activities	6	1,503,518	40,711	15,740	1,559,969	337,880
Total		1,763,129	40,711	15,740	1,819,580	537,850
Net income/(expenditure) before gains on investments		(309,954)	(40,711)	(740)	(351,405)	109,854
Net (losses)/gains on investments	11	(29,586)	-	-	(29,586)	385,562
Net income/(expenditure)		(339,540)	(40,711)	(740)	(380,991)	495,416
Transfers between funds	16	(1,550,520)	1,553,020	(2,500)	-	-
Net movement in funds		(1,890,060)	1,512,309	(3,240)	(380,991)	495,416
Reconciliation of funds:						
Total funds brought forward		3,041,746	1,597,671	138,643	4,778,060	4,282,644
Total funds carried forward		£ 1,151,686	£ 3,109,980	£ 135,403	£ 4,397,069	£ 4,778,060

The notes on pages 24 to 34 form part of these financial statements.

YORK AGAINST CANCER
(Registration number: 06884476)

BALANCE SHEET
AS AT 31 DECEMBER 2022

	Note	Charity 2022 £	Consolidated 2022 £	Charity 2021 £	Consolidated 2021 £
FIXED ASSETS					
Tangible Fixed Assets	12	826,241	866,230	362,264	405,171
Investments	11	3,516,498	3,516,497	4,076,185	4,076,184
		4,342,739	4,382,727	4,438,449	4,481,355
CURRENT ASSETS					
Stock		-	60,521	-	55,176
Debtors	13	1,043,825	912,677	540,858	449,771
Cash at Bank and in Hand		811,874	863,649	819,603	846,463
		1,855,699	1,836,847	1,360,461	1,351,410
CREDITORS: amounts falling due within one year	14	1,055,560	1,091,095	498,519	517,503
NET CURRENT ASSETS		800,139	745,752	861,942	833,907
TOTAL ASSETS LESS CURRENT LIABILITIES		5,142,878	5,128,479	5,300,391	5,315,262
CREDITORS: amounts falling due after one year	15	731,410	731,410	537,202	537,202
NET ASSETS		£ 4,411,468	£ 4,397,069	£ 4,763,189	£ 4,778,060
THE FUNDS OF THE CHARITY					
Unrestricted					
Undesignated	18	1,206,074	1,151,686	3,069,782	3,041,746
Designated	16,18	3,069,991	3,109,980	1,554,764	1,597,671
Restricted	17,18	135,403	135,403	138,643	138,643
TOTAL CHARITY FUNDS		£ 4,411,468	£ 4,397,069	£ 4,763,189	£ 4,778,060

Approved by the Trustees on 6 June 2023 and signed on its behalf by:

S B Wearing
Director and Trustee

The notes on pages 24 to 34 form part of these financial statements.

**YORK AGAINST CANCER
CONSOLIDATED CASHFLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Note	2022 £	2021 £
Cash flows from operating activities:			
Net cash used in operating activities	21	(226,911)	(335,263)
Cash flows from investing activities:			
Dividends, interest and rents from investments		36,438	45,102
Purchase of property, plant and equipment		(322,442)	(64,330)
Proceeds from sale of property		-	251,731
Proceeds from sales of investments		1,475,082	1,838,749
Purchase of investments		(944,981)	(1,788,361)
Net cash provided by investing activities		<u>244,097</u>	<u>282,891</u>
Change in cash and cash equivalents in the reporting period		17,186	(52,372)
Cash and cash equivalents at the beginning of the reporting period		<u>846,463</u>	<u>898,835</u>
Cash and cash equivalents at the end of the reporting period		<u>£ 863,649</u>	<u>£ 846,463</u>

The notes on pages 24 to 34 form part of these financial statements.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property	at straight line over 50 years or life of lease
Equipment	
- Shop and office equipment	at straight line over 10 years
- Computer equipment	at straight line over 3 years
- Respite home equipment	at straight line over 4 years
- Motor vehicles	at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2022. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

Government grants

These government grants relate to the COVID grants for retail closures issued to the subsidiary trading company.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

2. DONATIONS AND LEGACIES	Unrestricted £	Restricted £	2022 £	2021 £
Donations and grants	213,697	15,000	228,697	158,533
In Memoriam	26,509	-	26,509	19,852
Legacies	909,636	-	909,636	206,699
Government grant	-	-	-	13,431
Intangible income	5,000	-	5,000	5,000
	£ 1,154,842	£ 15,000	£ 1,169,842	£ 403,515

During the year the charity was notified of a potential further £157,000 in legacy income from various estates the timing and amounts still remain uncertain and therefore have not been provided for.

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES	2022 £	2021 £
Fundraising income	136,121	99,601
Subsidiary's non-charitable trading turnover	125,774	99,486
	£ 261,895	£ 199,087

4. INVESTMENTS	2022 £	2021 £
Interest received	1,210	627
Dividends received	35,228	44,475
	£ 36,438	£ 45,102

5. ANALYSIS OF RAISING FUNDS	Unrestricted £	Restricted £	2022 £	2021 £
Advertising	6,639	-	6,639	11,292
Fundraising costs	80,727	-	80,727	36,933
Non charitable trading - other costs	115,039	-	115,039	110,546
Non charitable trading - staff costs	34,601	-	34,601	21,123
Non charitable trading - depreciation	5,405	-	5,405	5,156
Investment fees	17,200	-	17,200	14,920
	£ 259,611	£ -	£ 259,611	£ 199,970

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

6. ANALYSIS OF CHARITABLE ACTIVITIES

<i>Direct project costs:</i>	Unrestricted £	Restricted £	2022 £	2021 £
Research				
Jack Birch Unit	353,262	10,000	363,262	-
Clinical Trial Nurses	152,221	-	152,221	95,051
Support and Care				
Cancer Care Centre - Old	-	-	-	6,511
Leveson Centre	37,378	-	37,378	-
Respite property expenses	22,653	-	22,653	21,103
Minibus running costs - direct	11,882	-	11,882	12,248
Minibus running costs - staff costs	21,273	-	21,273	20,439
Mobile Chemotherapy Unit*	-	5,740	5,740	(104,381)
Transport - Rapid diagnostics	7,086	-	7,086	-
Psychology services	10,805	-	10,805	4,040
Robotic surgery	680,000	-	680,000	-
One off costs	150	-	150	-
Health Care Assistant	-	-	-	12,818
Health Welfare Advisor	-	-	-	73,444
Education				
Education expenses	8,850	-	8,850	2,588
	1,305,560	15,740	1,321,300	143,861
Support costs:				
Staff costs	154,175	-	154,175	139,079
Staff training and travel	3,666	-	3,666	2,553
Rent, service charge and rates	16,871	-	16,871	21,779
Heat and light	3,756	-	3,756	1,837
Repairs and maintenance	1,510	-	1,510	173
Insurances	4,318	-	4,318	3,416
Printing, stationery and postage	4,913	-	4,913	4,870
Computer expenses	11,516	-	11,516	7,819
Telephone	800	-	800	2,693
Sundry expenses	4,176	-	4,176	6,384
Gains and losses on fixed assets	-	-	-	(28,554)
Depreciation	19,370	-	19,370	16,168
	225,071	-	225,071	178,217
Governance costs:				
Audit fees	4,560	-	4,560	4,560
Accountancy fees	7,400	-	7,400	7,507
Legal fees	-	-	-	2,182
Bank charges	1,638	-	1,638	1,553
	13,598	-	13,598	15,802
Total charitable activities	£ 1,544,229	£ 15,740	£ 1,559,969	£ 337,880

*During 2021 the underspend on the Mobile Chemotherapy Unit was released as the project cost less than initially budgeted. Running costs will be covered by the restricted funds in future years.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

7. NET INCOMING RESOURCES FOR THE YEAR

	2022 £	2021 £
This is stated after charging:		
Depreciation	24,775	21,324
Auditor's remuneration for audit services - charity	4,560	4,560

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

	2022 £	2021 £
Wages and salaries	185,048	160,955
Social security costs	11,194	8,614
Pension costs	7,602	6,701
Recruitment costs	3,120	-
Medical Insurance	3,085	4,371
	£ 210,049	£ 180,641

The average monthly head count was 8 staff (2021 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Projects	1	1
Trading	1	1
Management and administration	6	6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees, the CEO and Deputy CEO following the restructure. The total employee benefits of the key management personnel of the Charitable Company were £88,781 (2021 - £50,303).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £138,024 (2021 £92,808). Interest of £nil (2021 £186) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

	2022 £	2021 £
Turnover	125,774	99,486
Cost of sales	(61,578)	(64,071)
Gross profit	64,196	35,415
Administrative expenses	(93,467)	(72,754)
Operating profit	(29,271)	(37,339)
Other operating income	-	15,333
Interest payable	-	(186)
Profit on ordinary activities before taxation	(29,271)	(22,192)
Taxation	-	-
Profit on ordinary activities after taxation	(29,271)	(22,192)
Amount gifted to York Against Cancer	-	-
Retained (withdrawn from)/within Subsidiary	£ (29,271)	£ (22,192)
Net Assets	£ (14,399)	£ 14,871

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

11. INVESTMENTS

Consolidated	2022 £	2021 £
Market value at 1 January 2022	4,076,184	3,741,010
Additions at cost	944,981	1,788,361
Disposals	(1,475,082)	(1,838,749)
Revaluations	(29,586)	385,562
Market value at 31 December 2022	<u>£ 3,516,497</u>	<u>£ 4,076,184</u>
Analysis of investments by class:		
Listed investments	<u>£ 3,516,497</u>	<u>£ 4,076,184</u>
The historical cost of the above investments amounts to:	<u>£ 3,196,719</u>	<u>£ 3,633,156</u>

The following material investments are over 5% by value of the investments held

	2022 Market value £	2021 Market value £
Ruffer Charity Assets Trust Account	<u>1,832,547</u>	<u>2,231,923</u>
	<u>£ 1,832,547</u>	<u>£ 2,231,923</u>

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

	Property £	Motor Vehicles £	Equipment £	Charity Total £	Subsidiary - Shop Equipment £	Consolidated Total £
<i>Cost</i>						
At 1 January 2022	367,702	41,515	40,333	449,550	51,561	501,111
Additions in year	432,228	46,936	4,183	483,347	2,487	485,834
Disposals in year		-	(673)	(673)		(673)
At 31 December 2022	<u>799,930</u>	<u>88,451</u>	<u>43,843</u>	<u>932,224</u>	<u>54,048</u>	<u>986,272</u>
<i>Depreciation</i>						
At 1 January 2022	36,771	37,342	13,173	87,286	8,654	95,940
Charge for year	7,354	5,880	6,136	19,370	5,405	24,775
Disposals in year		-	(673)	(673)		(673)
At 31 December 2022	<u>44,125</u>	<u>43,222</u>	<u>18,636</u>	<u>105,983</u>	<u>14,059</u>	<u>120,042</u>
<i>Net book value</i>						
At 31 December 2022	<u>£ 755,805</u>	<u>£ 45,229</u>	<u>£ 25,207</u>	<u>£ 826,241</u>	<u>£ 39,989</u>	<u>£ 866,230</u>
At 31 December 2021	<u>£ 330,931</u>	<u>£ 4,173</u>	<u>£ 27,160</u>	<u>£ 362,264</u>	<u>£ 42,907</u>	<u>£ 405,171</u>

All fixed assets are held for direct charitable purposes in Designated Funds.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

13. DEBTORS	Charity 2022 £	Consolidated 2022 £	Charity 2021 £	Consolidated 2021 £
Amounts owed by subsidiary	138,024	-	92,809	-
Prepayments	13,396	20,272	6,488	6,596
Accrued income	892,405	892,405	430,000	430,000
Other debtors	-	-	11,561	13,175
	£ 1,043,825	£ 912,677	£ 540,858	£ 449,771

**14. CREDITORS: amounts falling due
within one year**

Trade creditors	176,204	182,320	2,445	3,488
Project creditors	827,466	827,466	476,711	476,711
Taxation and social security	3,802	4,201	3,146	6,325
Accruals	45,342	74,362	14,187	28,949
Other creditors	2,746	2,746	2,030	2,030
	£ 1,055,560	£ 1,091,095	£ 498,519	£ 517,503

**15. CREDITORS: amounts falling due
after one year**

Project creditors	£ 731,410	£ 731,410	£ 537,202	£ 537,202
-------------------	------------------	------------------	------------------	------------------

16. DESIGNATED FUNDS (consolidated)

Designated Funds - 2022	Balance 01/01/2022 £	Income £	Expenditure £	Transfers £	Balance 31/12/2022 £
Leveson Centre	466,500	-	-	87,250	553,750
On demand services	10,000	-	(7,086)	63,086	66,000
Education Project	-	-	(8,850)	18,850	10,000
Minibus	36,000	-	-	(36,000)	-
Health Welfare	-	-	-	114,000	114,000
Jack Birch Unit	-	-	-	1,500,000	1,500,000
Robotic Surgery Project	680,000	-	-	(680,000)	-
Fixed Assets Fund	405,171	-	(24,775)	485,834	866,230
Total	£ 1,597,671	£ -	£ (40,711)	£ 1,553,020	£ 3,109,980

Designated Funds - 2021	Balance 01/01/2021 £	Income £	Expenditure £	Transfers £	Balance 31/12/2021 £
Leveson Centre	-	-	-	466,500	466,500
On demand services	10,000	-	-	-	10,000
Education Project	-	-	(2,588)	2,588	-
Minibus	28,000	-	-	8,000	36,000
Robotic Surgery Project	-	-	-	680,000	680,000
Fixed Assets	585,342	-	7,230	(187,401)	405,171
Complementary Therapy	6,364	-	(6,364)	-	-
Cancer Care Centre	5,382	-	(5,382)	-	-
Total	£ 635,088	£ -	£ (7,104)	£ 969,687	£ 1,597,671

Leveson Centre

The charity has set aside the remaining budget for improvements relating to the Leveson Centre as the year end and 5 years of lease costs.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

16. DESIGNATED FUNDS (consolidated continued)

On demand services

The trustees have set aside monies to fund the following on demand services - patient travel for rapid diagnostics, complementary therapy and teenage psychology services. These services levels are set budgets at the beginning of each year based on current demand.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

Minibus

The trustees have set aside monies for the purchase of a new minibus which was purchased in the year.

Health Welfare

The board wish to fund an additional health welfare post for 3 years in the York area and have ring fenced the following monies.

Jack Birch Unit

The Jack Birch Unit grant is up for renewal in 2024 and the trustees wish to continue this support the on-going research. Investments of £1.5m has been designated to ensure the charity can fund the continued support in 2024.

Robotic Surgery Project

During the year the charity committed to support the NHS regarding its Robotic Surgery facilities. The commitment of £680,000 has been recognised in the current year and will be paid over 3 years.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

Cancer Care Centre

The Board was committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

17. RESTRICTED FUNDS (consolidated)

	Balance 01/01/2022	Income	Expenditure	Transfers	Balance 31/12/2022
Restricted Funds - 2022	£	£	£	£	£
Mobile Chemotherapy Unit	136,966	2,500	(5,740)	-	133,726
Minibus Appeal	-	2,500	-	(2,500)	-
Jack Birch Unit	-	10,000	(10,000)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2022	£ 138,643	£ 15,000	(£ 15,740)	(£ 2,500)	£ 135,403
Restricted Funds - 2021	Balance 01/01/2021	Income	Expenditure	Transfers	Balance 31/12/2021
	£	£	£	£	£
Mobile Chemotherapy Unit	142,348	-	(5,382)	-	136,966
Mouth Cancer	1,677	-	-	-	1,677
Total 2021	£ 144,025	£ -	(£ 5,382)	£ -	£ 138,643

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Minibus Appeal

Monies were received for the purchase of a new minibus which was purchased in the year.

Jack Birch Unit

Monies were received for support of the Jack Birch Unit which were used during the year.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

	General Funds £	Designated Funds £	Restricted Funds £	Total 2022 £
Fund balances at 31 December 2022 are represented by:				
Tangible fixed assets	-	866,230	-	866,230
Investments	2,016,497	1,500,000	-	3,516,497
Current assets	957,694	743,750	135,403	1,836,847
Current liabilities	(1,091,095)	-	-	(1,091,095)
Long term liabilities	(731,410)	-	-	(731,410)
	£ 1,151,686	£ 3,109,980	£ 135,403	£ 4,397,069
	General Funds £	Designated Funds £	Restricted Funds £	Total 2021 £
Fund balances at 31 December 2021 are represented by:				
Tangible fixed assets	-	405,171	-	405,171
Investments	4,076,184	-	-	4,076,184
Current assets	1,163,021	49,746	138,643	1,351,410
Current liabilities	(517,503)	-	-	(517,503)
Long term liabilities	(537,202)	-	-	(537,202)
	£ 4,184,500	£ 454,917	£ 138,643	£ 4,778,060

19. OPERATING LEASE COMMITMENTS

As at 31 December 2022 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

	At 31 December 2022		At 31 December 2021	
	Land and buildings £	Office equipment £	Land and buildings £	Office equipment £
Total operating leases payable:				
Within one year	115,905	-	40,298	-
Between two and five years	335,370	-	45,684	-
After five years	278,273	-	2,486	-

20. RELATED PARTIES

During the year the Charitable Company paid £3,097 (2021 £2,829) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2021 £107) owing to HPH Chartered Accountants.

During the year the Charitable Company paid £nil (2021 £2,160) to Harrowells Solicitors for legal fees, a firm in which the Charitable Company's Director, Robert Onyett, is a director.

During 2021 the wife of a director Ian Yeowart was paid £1,300 for temporary employment cover. No payments were made in 2022.

During the year trustees and related parties donated £116,384 (2021 £50,100) to the charity.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

21. CASH FLOW NOTES

RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES	2022 £	2021 £
Net income/(expenditure) for the reporting period	(380,991)	495,416
Adjustments for:		
Depreciation charges	24,775	21,324
Gains on sale of fixed assets	-	(28,554)
(Gains)/Losses on investments	29,586	(385,562)
Dividends, interest and rents from investments	(36,438)	(45,102)
(Increase)/Decrease in stocks	(5,345)	119
Increase in debtors	(462,906)	12,514
(Increase)/Decrease in creditors	604,408	(405,418)
Net cash used in operating activities	£ (226,911)	£ (335,263)
ANALYSIS OF CASH AND CASH EQUIVALENTS		
Cash at bank and in hand	863,649	846,463
Total cash and cash equivalents	£ 863,649	£ 846,463

ANALYSIS OF CHANGES IN NET DEBT

	At 01/01/2022 £	Cash-flows £	At 31/12/2022 £
Cash	846,463	15,542	862,005

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

YORK AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

24. COMPARATIVE INFORMATION

	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2021 £
Income and endowments from:				
Donations and legacies	403,515	-	-	403,515
Other trading activities	199,087	-	-	199,087
Investments	45,102	-	-	45,102
Total	647,704	-	-	647,704
Expenditure on:				
Raising funds	199,970	-	-	199,970
Charitable activities	325,394	7,104	5,382	337,880
Total	525,364	7,104	5,382	537,850
Net expenditure before losses on investments	122,340	(7,104)	(5,382)	109,854
Net gains on investments	385,562	-	-	385,562
Net income/(expenditure)	507,902	(7,104)	(5,382)	495,416
Transfers between funds	(969,687)	969,687	-	-
Net movement in funds	(461,785)	962,583	(5,382)	495,416
Reconciliation of funds:				
Total funds brought forward	3,503,531	635,088	144,025	4,282,644
Total funds carried forward	£ 3,041,746	£ 1,597,671	£ 138,643	£ 4,778,060

25. CAPITAL COMMITMENTS

At the year end the charity was committed to spend £250,000 for the completion of the Leveson Centre fit out. These funds have been designated.